Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Vaccinex Inc (NQ: VCNX )

3.730 +0.350 (+10.36%)
Streaming Delayed Price Updated: 12:23 PM EDT, Oct 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,720
Open 3.500
Bid (Size) 3.660 (2)
Ask (Size) 3.730 (43)
Prev. Close 3.380
Today's Range 3.377 - 3.990
52wk Range 1.390 - 13.45
Shares Outstanding 65,941,086
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
In addition to cognitive benefit, pepinemab is believed to preserve vascular integrity in brain, a key consideration to avoid toxicity in Alzheimer’s disease 
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga

Performance

YTD
-64.66%
-64.66%
1 Month
+11.01%
+11.01%
3 Month
-56.43%
-56.43%
6 Month
-36.24%
-36.24%
1 Year
-70.90%
-70.90%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024
Via InvestorPlace
VCNX Stock Earnings: Vaccinex Reported Results for Q1 2024
Via InvestorPlace
VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
Via InvestorPlace
What's Going On With Vaccinex Stock Wednesday?
Via Benzinga
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
From Vaccinex, Inc.
Via GlobeNewswire
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.